Post-IPO stock offer preps Supernus for launch of epilepsy drugs
This article was originally published in Scrip
Supernus Pharmaceuticals has priced an underwritten public offering of six million shares of common stock at $8 per share for net proceeds of $44.7 million for the commercial launch of the newly public company's epilepsy drugs Oxtellar XR and Trokendi XR, clinical development of Phase II attention-deficit hyperactivity disorder (ADHD) drug candidates SPN-810 and SPN-812, and repayment of debt and other expenses.
You may also be interested in...
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.
The company has assembled small molecule discovery capabilities for the development of targeted cancer drugs that it believes rivals big pharma efforts and will fulfill patients’ unmet needs.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.